Arthneeti
RB

Rossari Biotech Ltd

Q1 FY27Chemicals & Petrochemicals

Rossari Biotech Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹442
Market cap₹2.4K Cr
P/E16.1
Updated23 Sept 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned

The short version

FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13). Rossari targets over 15% top-line growth annually, as reiterated for FY27 despite current global uncertainties.

From Rossari Biotech Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Moderate growth
  • FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13).
  • Growth driven by ramp-up in utilization of new capacity and new products from recent expansions (Page 7).
  • Volume growth in Q1 was about 10%, with the remainder of top-line growth from price increases (Page 12).
  • Increased EO capacity expected by end of FY27 to drive healthy growth in FY27 and FY28 (Pages 12, 13).
  • New product introductions like vitamin premixes, enzymes, esters, and pharma segment to support volume expansion (Pages 11, 12).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Current CAPEX in India has slowed down; only calibrated spending on new CAPEX is planned, focusing on new products/molecules such as pharma and aroma chemicals.
  • No large CAPEX planned for this year; focus is on utilizing existing capacities efficiently.
  • Early-stage operational and exploratory expenses have begun for the Saudi Arabia (KSA) greenfield project, despite the West Asia geopolitical situation.
  • The KSA project remains a key strategic initiative, with active engagement with partners, suppliers, consultants, and the Saudi ministry; plans include setting up downstream EO and non-EO products.
  • Expected gestation for KSA production start is around 1.5 years from investment announcement.

2 more points management made on capital expenditure plans

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit details about the current or expected order book or pending orders for Rossari Biotech. However, relevant insights include: - The company is scaling up its operations, aiming to more than double its size over the next four years. - There is ongoing investment and seeding in new markets and capacities, such as the Thailand plant and Saudi Arabia initiative. - Capacity utilization is improving steadily across expanded capabilities. - Increased visibility and availability of Ethylene Oxide (EO) are expected, which should support growth. - The company continues to focus on customer interactions, exhibitions, and market presence to drive growth.

2 more points management made on order book & pipeline

Rossari Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹685 Cr, net profit ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Rossari Biotech Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Prasol Chemicals Ltd (Q1 FY27)

    Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank

  • Vipul Organics Ltd (Q1 FY27)

    Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…

  • Fine Organic Industries Ltd (Q1 FY27)

    Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

  • Chemfab Alkalis Ltd (Q1 FY27)

    Consolidated Q1FY27 Revenue from Operations:** ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Key concall takeaways from Chemfab Alkalis Ltd's Q1…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Rossari Biotech Ltd Q1 FY27 results?

FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13). Rossari targets over 15% top-line growth annually, as reiterated for FY27 despite current global uncertainties.

What is Rossari Biotech Ltd share price analysis?

Rossari Biotech Ltd currently shows a below-average growth signal. The stock trades at a P/E of 16.1 with a market cap of ₹2,426 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech Ltd planning capital expenditure?

Current CAPEX in India has slowed down; only calibrated spending on new CAPEX is planned, focusing on new products/molecules such as pharma and aroma chemicals.

Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.